Instructions de recherche:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Parcourir les contenus (73 total)
-
Créateur: ACTT- Study Group
Sujet: Treatment & Care
Type d'élément: Publication
Date de la dernière mise à jour: 2022-05-23
Description: Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to… -
Créateur: Theodore J Cieslak, Jocelyn J Herstein, Mark G Kortepeter, Angela L Hewlett
Sujet: Treatment & Care
Type d'élément: Publication
Date de la dernière mise à jour: 2019-08-22
Description: Although the concept of high-level containment care (HLCC or ‘biocontainment’), dates back to 1969, the 2014–2016 outbreak of Ebola virus disease (EVD) brought with it a renewed emphasis on the use of specialized HLCC units in the care of patients… -
Créateur: Rosas, Ivan O., Norbert Bräu, Michael Waters, Ronaldo C. Go, Bradley D. Hunter, Sanjay Bhagani, Daniel Skiest, Mariam S. Aziz, Nichola Cooper, Ivor S. Douglas, Sinisa Savic, Taryn Youngstein, Lorenzo Del Sorbo, Antonio Cubillo Gracian, David J. De La…
Sujet: Treatment & Care
Type d'élément: Publication
Date de la dernière mise à jour: 2021-04-22
Description: Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better… -
Créateur: NETEC
Sujet: Treatment & Care
Type d'élément: Webinaire
Date de la dernière mise à jour: 2020-11-20
Description: In this webinar, we will discuss the challenges involved when obtaining informed consent from a hospitalized patient who is in isolation related to COVID-19, articulate the obstacles and strategies involved when conducting research during a pandemic… -
Créateur: Garibaldi, B. T., J. Fiksel, J. Muschelli, M. L. Robinson, M. Rouhizadeh, J. Perin, G. Schumock, P. Nagy, J. H. Gray, H. Malapati, M. Ghobadi-Krueger, T. M. Niessen, B. S. Kim, P. M. Hill, M. S. Ahmed, E. D. Dobkin, R. Blanding, J. Abele, B. Woods,…
Sujet: Treatment & Care
Type d'élément: Publication
Date de la dernière mise à jour: 2020-09-22
Description: Risk factors for progression of coronavirus 2019 (COVID-19) to severe disease or death are underexplored in U.S. cohorts. -
Créateur: Solomon, Isaac H., Erica Normandin, Shamik Bhattacharyya, Shibani S. Mukerji, Kiana Keller, Ahya S. Ali, Gordon Adams, Jason L. Hornick, Robert F. Padera, and Pardis Sabeti.
Sujet: Treatment & Care
Type d'élément: Publication
Date de la dernière mise à jour: 2020-09-03
Description: Neurologic symptoms, including headache, altered mental status, and anosmia, occur in many patients with Covid-19. -
Créateur: Keita, Mory, Boubacar Diallo, Samuel Mesfin, Abdourahmane Marega, Koumpingnin Yacouba Nebie, N'Faly Magassouba, Ahmadou Barry, Seydou Coulibaly, Boubacar Barry, Mamadou Oury Baldé, Raymond Pallawo, Sadou Sow, Alpha Oumar Bah, Mamadou Saliou Balde,…
Sujet: Treatment & Care
Type d'élément: Publication
Date de la dernière mise à jour: 2019-09-04
Description: A record number of people survived Ebola virus infection in the 2013–16 outbreak in west Africa, and the number of survivors has increased after subsequent outbreaks. -
Créateur: FDA
Sujet: Research
Type d'élément: Lien hypertexte
Date de la dernière mise à jour: 2023-05-12
Description: The Emergency Use Authorization (EUA) authority allows FDA to help strengthen the nation’s public health protections against chemical, biological, radiological, and nuclear (CBRN) threats including infectious diseases, by facilitating the… -
Créateur: FDA
Sujet: Research
Type d'élément: Lien hypertexte
Date de la dernière mise à jour: 2022-07-20
Description: Current Federal law requires that a drug be the subject of an approved marketing application before it is transported or distributed across state lines. Because a sponsor will probably want to ship the investigational drug to clinical investigators… -
Créateur: Editor Bruce Hawkins
Sujet: Research
Type d'élément: Publication
Date de la dernière mise à jour: 2019
Description: The purpose of these guidelines is to describe a standardized approach for the management of investigational drug products by the clinical research pharmacy, pharmaceutical industry, and cooperative and research network groups.